Esperion Therapeutics (ESPR) Change in Accured Expenses (2012 - 2026)

Esperion Therapeutics has reported Change in Accured Expenses for 15 years, with the latest figure at -$4.9 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses fell 421.89% year-over-year to -$4.9 million; the trailing twelve-month figure through Mar 2026 stood at $27.3 million (up 39.73% YoY), and the FY2025 full-year result was $31.2 million, up 70.23% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$4.9 million, down from $12.7 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $21.2 million in Q3 2025, with the low at -$4.9 million in Q1 2026.
• Historically, Change in Accured Expenses has averaged $4.2 million across 5 years, with a median of $1.2 million in 2022.
• Annual changes were most pronounced in 2023 — Change in Accured Expenses jumped 690.34% — and 2026, when it slumped 421.89%.
• Esperion Therapeutics' Change in Accured Expenses stood at $1.2 million in 2022, then soared by 566.8% to $8.2 million in 2023, then dropped by 22.55% to $6.3 million in 2024, then soared by 100.41% to $12.7 million in 2025, then slumped by 138.24% to -$4.9 million in 2026.
• The last three Change in Accured Expenses figures came in at -$4.9 million (Q1 2026), $12.7 million (Q4 2025), and $21.2 million (Q3 2025), per Business Quant data.